ACM Biolabs

Sweden
Slite, Gotland, Sweden, 638075

Company profile

ACM Biolabs company profile

ACM Biolabs focuses on developing novel vaccines and antibodies using proprietary artificial cell membrane ("ACM"​) technology. ACM is able to incorporate functional, folded membrane proteins into the artificial cell membranes which keeps them stable, allowing them to induce a strong immune reaction. ACM has demonstrated efficacy via both injected and oral dosages using synthesized membrane proteins and has a growing pipeline of vaccines and antibodies. The company is headquartered in Singapore, and has been operational since 2013.

Business identity

Contact email
[email protected]
Phone number
+65 6265 5646
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Postal code
638075
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$6.8M
Last funding
Series Unknown / $6.8M / 2022-09-22
Last equity funding
Series Unknown / $6.8M
Investors
1
Lead investors
1
Founders
1
Articles
8

Founders and investors

Founders

Madhavan Nallani

Lead investors

Ritz Venture Capital

Investors

Ritz Venture Capital